Author: Oliver Darlington

Oliver is a health economist and market access professional with multi-country multi-therapy area experience. Oliver has led diverse teams of technical and commercial experts to quantify and communicate disease burden and cost-effectiveness and achieve successful reimbursement across a wide range of complex disease areas, including oncology, antimicrobials, and CVRM. Oliver has designed and implemented de novo cost-effectiveness and policy models to support reimbursement and peer-reviewed publications.